The study investigates the efficacy and safety of MEZId, an oral CELMoD™ agent, in combination with novel therapeutic agents (TAZ, BMS-986158, TRAM) in patients with relapsed/refractory multiple myeloma (RRMM). The CA057-003 trial (NCT05372354) explores triplet combinations targeting dysregulated oncogenic pathways identified in RRMM, showing promising outcomes in terms of response rates and safety profiles. 

Key Points:

• MEZId combined with TAZ, BMS-986158, or TRAM demonstrated significant efficacy in RRMM.
• Primary endpoints included defining recommended phase 2 doses and safety evaluations.
• Common adverse events included neutropenia, with manageable non-hematologic toxicities.
• Responses, including stringent complete responses, were observed across all cohorts.
• Pharmacodynamic assessments confirmed the activity of MEZI across combination regimens.

Authors:
Luciano J. Costa, MD, PhD; Fredrik Schjesvold, MD, PhD; Rakesh Popat, MBBS, PhD; David Siegel; Saad Z. Usmani, MD; Syed Abbas Ali; Michael P. Chu, MD; Monique A. Hartley-Brown, MD; Nizar J. Bahlis; Albert Oriol; Joaquín Martínez Lopez; Enrique M. Ocio; Karthik Ramasamy; Donna Reece, MD; Emma Searle; Allison Gaudy; Antonina Kurtova; Wen Zhang; Rafael Sarmiento; August Dietrich; Jessica Katz; Michael Pourdehnad, MD; Paul G. Richardson